Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $2.06
Previous CloseN/A
Volume1.89M
Average Volume (3M)4.21M
Market Cap
$201.61M
Enterprise Value$244.09M
Total Cash (Recent Filing)$58.06M
Total Debt (Recent Filing)$1.75M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 02, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding292,014,470
10 Day Avg. Volume4,174,329
30 Day Avg. Volume4,207,993
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)43.54
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit60.19
Enterprise Value/Ebitda-4.62
Forecast
1Y Price Target
$6.67Price Target Upside826.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported $0.8M of revenues, compared to consensus estimate of $0.4M and a net loss of $0.05 per share, in line with consensus estimated net loss of $0.05 per share.
Market PotentialDME remains a significant area of unmet need with 30%-40% of patients not responding to standard therapy, indicating a large potential market for OCU200.
Regulatory ProgressThe FDA lifted the clinical hold on OCU200's IND for a Phase 1 study targeting Diabetic Macular Edema, which indicates regulatory progress.
Bears Say
Financial LossOcugen reported a net loss of ($13.9M) for 4Q24 and ($54.1M) for the full year, with $58.8M in cash, providing runway into 1Q26.
Funding RequirementsManagement plans to design a Phase 3 pivotal study based on the results from the Phase 2 during 2026, pending the availability of funds.
---
Ownership Overview
1.15% Insiders
8.26% Mutual Funds
0.02% Other Institutional Investors
81.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $2.06 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $201.61M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is May 02, 2025 which is in 5 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Mar 05, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.052 by $0.002.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 292,014,470 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.052. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
---
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (826.39% Upside)
$6.67 (826.39% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 65.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.17%
12-Months-Change
Fundamentals
Return on Equity
-154.01%
Trailing 12-Months
Asset Growth
27.31%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
---
OCGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Ocugen highlighted several strategic advancements, including FDA alignment for an expedited clinical trial timeline, positive clinical trial results, and a strong financial position bolstered by recent funding. However, the company also reported increased net losses and higher expenses compared to the previous year. While the company faces financial challenges, the progress in clinical trials and regulatory advancements contribute positively to its outlook.Read More>---
OCGN Stock 12 Month Forecast
Average Price Target
$6.67
▲(826.39% Upside)
Technical Analysis
Cidara Therapeutics
―
Corvus Pharmaceuticals
―
Foghorn Therapeutics
―
Tevogen Bio Holdings
―
enGene Holdings
―
Best Analysts Covering OCGN
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+20.06%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +20.06% per trade.
---